Robert Woods, MD
Cardiovascular Disease · Lebanon, TNNPI 1457465668
Payments from drug & device makers
Across 658 payments — averaging $41.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$15K
- Actelion Pharmaceuticals US, Inc.$3K
- Johnson & Johnson$1K
- Boehringer Ingelheim$1K
- Medtronic$1K
- Amgen$575
- plus $5K from 25 others
What the payments were for
- Speaking & faculty fees$11,50042%
- Food & beverage$15,76258%
- Education$760%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 91 | $15,270 |
| Actelion Pharmaceuticals US, Inc. | 130 | $3,108 |
| Johnson & Johnson | 99 | $1,403 |
| Boehringer Ingelheim | 71 | $1,383 |
| Medtronic | 8 | $1,068 |
| Amgen | 30 | $575 |
| Merck | 25 | $572 |
| Esperion Therapeutics, Inc. | 11 | $479 |
| Pfizer | 32 | $461 |
| E.r. Squibb & Sons, L.L.C. | 33 | $408 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $363 |
| AstraZeneca | 22 | $352 |
| Novartis | 27 | $349 |
| Edwards Lifesciences | 8 | $284 |
| Sanofi-aventis U.S. LLC | 7 | $190 |
| Amarin Pharma, Inc. | 10 | $170 |
| Irhythm Technologies, Inc. | 2 | $154 |
| Abbott | 3 | $153 |
| Corcept Therapeutics | 1 | $115 |
| Biotronik NRO, Inc. | 5 | $93 |
| Biotronik Inc. | 4 | $62 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $59 |
| Novo Nordisk | 3 | $57 |
| Lexicon Pharmaceuticals, Inc. | 2 | $48 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $39 |
| Bayer | 2 | $28 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Philips North America LLC | 1 | $25 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Baxter Healthcare | 1 | $13 |
| Elutia, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$9,653
- Watchman$2,858
- WATCHMAN FLX$1,385
- Micra$856
- UPTRAVI$809
- OPSUMIT$606
- NEXLIZET$363
- NEXLETOL$363
- JARDIANCE$221
- AURORA EV-ICD MRI SURESCAN$160
- ASSURITY$117
- WINREVAIR$117
- Korlym$115
- EMBLEM$108
- PRALUENT$105
How this compares
$27,338 in reported general payments places this provider in the 80th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 602 | $616,263 |
| UptraviSelexipag | 17 | $536,549 |
| EliquisApixaban | 415 | $447,123 |
| OpsumitMacitentan | 16 | $294,752 |
| EntrestoSacubitril/Valsartan | 166 | $186,801 |
| Repatha SureclickEvolocumab | 89 | $86,266 |
| BrilintaTicagrelor | 55 | $37,852 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 350 | $21,373 |
| Metoprolol Succinate | 1,126 | $14,598 |
| JardianceEmpagliflozin | 12 | $12,319 |
| MultaqDronedarone Hcl | 15 | $11,780 |
| Nifedipine ErNifedipine | 239 | $9,619 |
| Atorvastatin Calcium | 825 | $8,505 |
| Amlodipine Besylate | 1,260 | $6,186 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 209 | $6,164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $3,108 | $831,30233 claims |
| Johnson & JohnsonXarelto | $1,403 | $616,263602 claims |
| PfizerEliquis | $461 | $447,123415 claims |
| NovartisEntresto | $349 | $186,801166 claims |
| AstraZenecaBrilinta | $352 | $37,85255 claims |
| Boehringer IngelheimJardiance | $1,383 | $12,31912 claims |
| Sanofi-aventis U.S. LLCMultaq | $190 | $11,78015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Lebanon
- Brian LindmanNashville$5.5M
- David MetzgerKingsport$4.8M
- Christopher EllisNashville$4.1M
- Dinesh GuptaNashville$3.2M
- Joann LindenfeldNashville$2.2M
- Frank McGrewMemphis$2.1M
- Rebecca HungNashville$1.8M
- Mohsin AlhaddadJackson$1.8M
- Robert SmithBrentwood$1.3M
- Travis RichardsonNashville$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.